Key facts
- This page summarizes Jeff Dykan's Form 3 filing for REGENTIS BIOMATERIALS LTD. (RGNT).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 18 Mar 2026, 16:30.
Jeff Dykan - 18 Mar 2026 Form 3 Insider Report for REGENTIS BIOMATERIALS LTD. (RGNT)
- Reporting relationship
- Director
- Issuer ticker
- RGNT
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 18 Mar 2026, 16:30:02 UTC
- Prior SEC filing
- 19 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeff Dykan
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jeff Dykan filed Form 3 for REGENTIS BIOMATERIALS LTD. (RGNT) on 18 Mar 2026.
Change
- Previous filing in this sequence was filed on 19 Sep 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001661229
Primary reporting owner
Dykan Jeff
- Relationship
- Director
- Address
- C/O REGENTIS BIOMATERIALS LTD., 60 MEDINAT HAYEHUDIM, HERZLIYA, ISRAEL
- Signature
- /s/ Jeff Dykan
- Signature date
- 18 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RGNT
holding
Ordinary Shares, no par value per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 270,473
- Date
- 18 Mar 2026
- Ownership
- See footnotes
- Footnotes
- F1, F2
RGNT
holding
Ordinary Shares, no par value per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 130,465
- Date
- 18 Mar 2026
- Ownership
- See footnotes
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RGNT
holding
Derivative
Warrants to purchase ordinary shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 6,122
- Exercise price
- $5.00
- Footnotes
- F3
RGNT
holding
Derivative
Warrants to purchase ordinary shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 2,083
- Exercise price
- $5.00
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Consists of Consists of (1) 270,473 ordinary shares held by SCP Vitalife Partners II L.P. ("SCPVP II"); (2) 130,465 ordinary shares held by SCP Vitalife Partners (Israel) II L.P. ("SCVP II Israel", and, with SCVP II, the "SCVP Entities").
Footnote F2
Reporting Person is the general partner of the SCVP Entities, and, as such, holds share voting and dispositive power over the shares held by SCVP Entities. The principal business address of SCP Vitalife Partners II L.P., is Messrs. Churchill and Weisman, 5 Great Valley Parkway, Suite 210, Malvern, Pennsylvania 19355. The principal business address of SCP Vitalife Partners (Israel) II L.P. is 15 Hatidhar, P.O. Box 2138, Raanana, Tel Aviv 4366517, Israel.
Footnote F3
The warrants are currently exercisable and have a 3 year term, held by SCP Vitalife Partners II L.P
Footnote F4
The warrants are currently exercisable and have a 3 year term, held by SCP Vitalife Partners (Israel) II L.P.